The metrics apply different weighting schemes to community structure. Observed richness counts detected taxa, whereas Chao1 gives greater attention to rare taxa when estimating richness. Shannon incorporates richness and the distribution of abundances, while Simpson places greater emphasis on common taxa and evenness. Selecting among them changes which features of a microbial community most influence the reported result.
Observed richness reflects the number of taxa detected in a sample, while Chao1 is designed to estimate richness with greater consideration of rare taxa. Consequently, communities containing many low-abundance taxa may be characterized differently by these measures. Comparing both can help distinguish the directly observed taxon count from a richness estimate influenced by rare members.
Shannon and Simpson provide information about how abundances are distributed across taxa, not only how many taxa occur. Shannon combines richness with abundance distribution, whereas Simpson emphasizes common taxa and evenness. Two samples can therefore have similar taxon counts but different index values if one community is more evenly distributed or dominated by a smaller number of common taxa.
Researchers derive these metrics from sequencing data for each biological sample, then compare the resulting values across defined patient groups, disease states, or treatment groups. The comparison can use a selected index or several indices together, allowing the analysis to examine observed richness, estimated richness, abundance distribution, and evenness rather than relying on a single description of community structure.
Cancer studies can apply these measures to microbial communities associated with tumors, the gut, or other relevant biological sites. Evaluating different sites helps characterize community structure in the context of the disease setting under investigation. The resulting comparisons may support analyses of how microbial diversity varies among patients, disease states, or treatment groups.
Differences in within-sample microbial diversity can be examined alongside therapeutic response, cancer progression, or factors associated with disease state. Comparing patient or treatment groups may reveal patterns in richness, abundance distribution, or evenness that are relevant to these outcomes. Such results support characterization of tumor-associated and other cancer-relevant microbiomes within broader research analyses.